Cargando…
Correction: Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595186/ https://www.ncbi.nlm.nih.gov/pubmed/28948029 http://dx.doi.org/10.1136/bmjdrc-2017-000391corr1 |
| _version_ | 1783263326000644096 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5595186 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | BMJ Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-55951862017-09-25 Correction: Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner BMJ Open Diabetes Res Care Correction BMJ Publishing Group 2017-09-07 /pmc/articles/PMC5595186/ /pubmed/28948029 http://dx.doi.org/10.1136/bmjdrc-2017-000391corr1 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| spellingShingle | Correction Correction: Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner |
| title | Correction: Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner |
| title_full | Correction: Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner |
| title_fullStr | Correction: Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner |
| title_full_unstemmed | Correction: Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner |
| title_short | Correction: Anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner |
| title_sort | correction: anagliptin ameliorates albuminuria and urinary liver-type fatty acid-binding protein excretion in patients with type 2 diabetes with nephropathy in a glucose-lowering-independent manner |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595186/ https://www.ncbi.nlm.nih.gov/pubmed/28948029 http://dx.doi.org/10.1136/bmjdrc-2017-000391corr1 |